1 Supplement Supplement Table 1. CD274 Loss, Neutral, and Gain in Various Diagnosis

Home , Acinar adenocarcinoma

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer

Supplement

Supplement Table 1. CD274 loss, neutral, and gain in various diagnosis CD274 CD274 CD274 Diagnosis N Loss Neutral Gain (%) (%) (%) lung adenocarcinoma 30396 48.5 36.3 15.1 colon adenocarcinoma (crc) 25618 19.3 55.6 25.0 breast carcinoma (nos) 14679 35.8 44.0 20.1 pancreas ductal adenocarcinoma 11698 56.3 35.2 8.5 prostate acinar adenocarcinoma 9466 28.6 55.0 16.4 lung squamous cell carcinoma (scc) 8852 52.6 29.5 17.9 breast invasive ductal carcinoma (idc) 8620 32.9 42.2 24.8 ovary serous carcinoma 7824 39.4 40.7 19.8 lung non-small cell lung carcinoma (nsclc) 6944 48.3 32.8 19.0 (nos) unknown primary adenocarcinoma 6329 48.2 38.0 13.8 rectum adenocarcinoma (crc) 5186 20.5 53.9 25.6 brain glioblastoma (gbm) 4787 36.1 54.6 9.3 liver cholangiocarcinoma 4653 48.0 39.8 12.2 bladder urothelial (transitional cell) 4443 42.0 39.6 18.4 carcinoma esophagus adenocarcinoma 4138 50.0 38.0 12.0 stomach adenocarcinoma (nos) 3979 40.6 45.0 14.4 head and neck squamous cell carcinoma 3511 31.0 43.3 25.7 (hnscc) skin melanoma 3501 55.4 36.6 8.1 unknown primary carcinoma (cup) (nos) 3432 41.1 40.2 18.7 uterus endometrial adenocarcinoma (nos) 3331 24.7 60.8 14.5 unknown primary melanoma 3038 51.4 37.7 11.0 ovary epithelial carcinoma 2564 37.7 41.8 20.5 lung small cell undifferentiated carcinoma 2493 21.4 51.6 27.0 pancreatobiliary carcinoma 2178 55.1 35.0 10.0 uterus endometrial adenocarcinoma 2113 16.6 71.7 11.7 endometrioid ovary high grade serous carcinoma 2025 41.1 37.8 21.1 uterus endometrial adenocarcinoma 1971 31.7 46.8 21.6 papillary serous kidney renal cell carcinoma 1675 48.2 40.1 11.7 gallbladder adenocarcinoma 1486 55.5 34.4 10.2 pancreas carcinoma (nos) 1481 55.1 34.4 10.5 gastroesophageal junction adenocarcinoma 1477 48.1 38.9 12.9 unknown primary squamous cell carcinoma 1414 39.7 36.8 23.6 (scc)

Huang RS.P, et al. J Immunother Cancer 2021; 9:e002680. doi: 10.1136/jitc-2021-002680 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer

fallopian tube serous carcinoma 1383 40.2 38.2 21.6 breast invasive lobular carcinoma (ilc) 1340 18.2 66.1 15.7 cervix squamous cell carcinoma (scc) 1317 14.4 54.3 31.3 kidney clear cell carcinoma 1299 48.0 41.5 10.5 uterus carcinosarcoma 1255 42.4 43.3 14.3 liver hepatocellular carcinoma (hcc) 1230 24.6 63.4 12.0 unknown primary undifferentiated 1181 33.1 51.7 15.2 neuroendocrine carcinoma esophagus squamous cell carcinoma (scc) 1087 49.7 31.8 18.5 appendix adenocarcinoma 1009 16.4 59.4 24.3 thyroid papillary carcinoma 868 24.0 65.9 10.1 brain glioma (nos) 824 29.6 55.7 14.7 ovary clear cell carcinoma 811 33.2 54.5 12.3 lung large cell neuroendocrine carcinoma 770 43.8 37.3 19.0 anus squamous cell carcinoma (scc) 758 12.5 59.5 28.0 pleura mesothelioma 750 34 46.9 19.1 peritoneum serous carcinoma 738 39.6 41.2 19.2 skin squamous cell carcinoma (scc) 729 40.1 34.6 25.4 cervix adenocarcinoma 700 24.4 57.0 18.6 brain meningioma 700 16.6 74.6 8.9 pancreas islet cell tumor 691 25.5 46.3 28.2 brain anaplastic astrocytoma 653 38.6 49.9 11.5 bile duct adenocarcinoma 652 50.5 37.6 12.0 unknown primary urothelial carcinoma 647 46.7 36.9 16.4 small intestine adenocarcinoma 622 36.5 47.1 16.4 kidney urothelial carcinoma 620 43.5 40.0 16.5 unknown primary (nos) 570 36.0 43.7 20.4 brain astrocytoma 566 28.3 58.5 13.3 duodenum adenocarcinoma 562 41.1 43.2 15.7 ampullary adenocarcinoma 561 51.5 37.4 11.1 ovary endometrioid adenocarcinoma 540 24.3 57.8 18.0 unknown primary serous carcinoma 536 42.9 38.6 18.5 ovary carcinosarcoma 488 55.1 31.4 13.5 unknown primary gist 487 39.4 53.0 7.6 thyroid carcinoma (nos) 472 25.2 63.6 11.2 adrenal gland cortical carcinoma 424 27.1 48.3 24.5 vulva squamous cell carcinoma (scc) 423 21.5 44.9 33.6 unknown primary neuroendocrine tumor 422 31.8 54.7 13.5 thyroid anaplastic carcinoma 404 28.2 41.3 30.4 ovary granulosa cell tumor 371 16.2 71.2 12.7 ureter urothelial carcinoma 367 43.1 38.7 18.3 lung adenosquamous carcinoma 351 49.6 32.5 17.9

uterus endometrial adenocarcinoma clear 348 39.4 44.3 16.4 cell lung sarcomatoid carcinoma 347 34.9 32.3 32.9 stomach gist 346 37.6 54.6 7.8 salivary gland carcinoma (nos) 342 39.8 40.6 19.6 head and neck adenoid cystic carcinoma 340 17.4 61.8 20.9 prostate neuroendocrine carcinoma 340 29.7 49.7 20.6 brain oligodendroglioma 329 23.4 72.0 4.6 salivary gland adenoid cystic carcinoma 317 13.6 67.2 19.2 brain astrocytoma pilocytic 312 25.6 57.1 17.3 unknown primary undifferentiated small cell 304 27.3 53.6 19.1 carcinoma breast metaplastic carcinoma 297 32.3 42.8 24.9 skin merkel cell carcinoma 296 17.6 72.3 10.1 colon neuroendocrine carcinoma 289 24.6 61.9 13.5 esophagus carcinoma (nos) 287 44.6 38.0 17.4 bladder carcinoma (nos) 282 35.1 44.7 20.2 eye intraocular melanoma 279 24.0 64.5 11.5 thymus carcinoma 272 19.9 57.0 23.2 thyroid medullary carcinoma 271 35.8 56.8 7.4 kidney renal papillary carcinoma 269 37.5 53.9 8.6 salivary gland adenocarcinoma 252 42.5 44.4 13.1 peritoneum mesothelioma 244 23.0 59.0 18.0 brain medulloblastoma 243 14.8 68.7 16.5 neuroblastoma 243 32.9 58.4 8.6 stomach adenocarcinoma diffuse type 225 34.7 48.4 16.9 small intestine gist 218 23.9 67.0 9.2 penis squamous cell carcinoma (scc) 207 21.3 43.5 35.3 prostate undifferentiated carcinoma 194 31.4 46.4 22.2 brain ependymoma 193 20.2 51.3 28.5 soft tissue fibromatosis 191 25.7 65.4 8.9 skin basal cell carcinoma 190 17.9 56.8 25.3 uterus endometrial adenocarcinoma mixed 187 26.7 56.1 17.1 histology ovary carcinoma mixed histology 174 37.9 46.0 16.1 bladder adenocarcinoma 171 32.2 36.8 31.0 appendix goblet cell carcinoid (gcc) 171 18.7 57.9 23.4 lung large cell carcinoma 168 47.0 39.3 13.7 skin adnexal carcinoma 167 28.1 49.7 22.2 thyroid follicular carcinoma 165 16.4 68.5 15.2 ovary mucinous carcinoma 164 46.3 41.5 12.2 thymus thymoma (nos) 159 13.8 52.2 34.0

nasopharynx and paranasal sinuses 157 33.8 45.2 21.0 undifferentiated carcinoma bladder squamous cell carcinoma (scc) 156 37.2 37.8 25.0 salivary gland duct carcinoma 154 58.4 28.6 13.0 lung atypical carcinoid 151 26.5 63.6 9.9 unknown primary adenoid cystic carcinoma 144 18.8 62.5 18.8 unknown primary sarcomatoid carcinoma 141 30.5 34.8 34.8 vagina squamous cell carcinoma (scc) 141 21.3 50.4 28.4 head and neck melanoma 140 47.9 40.0 12.1 small intestine neuroendocrine carcinoma 140 25.0 67.1 7.9 bone chordoma 139 55.4 32.4 12.2 kidney carcinoma (nos) 136 46.3 41.2 12.5 testis germ cell tumor (non-seminoma) 133 26.3 57.1 16.5 ovary low grade serous carcinoma 131 35.1 58.8 6.1 prostate ductal adenocarcinoma 130 27.7 60.0 12.3 anus melanoma 129 58.1 34.9 7.0 appendix mucinous neoplasm 128 14.8 58.6 26.6 pancreas acinar cell carcinoma 128 53.1 34.4 12.5 salivary gland acinic cell tumor 125 8.0 73.6 18.4 rectum squamous cell carcinoma (scc) 119 21.8 47.1 31.1 brain anaplastic oligodendroglioma 117 35.9 57.3 6.8 nasopharynx and paranasal sinuses 115 26.1 49.6 24.3 squamous cell carcinoma (scc) fallopian tube adenocarcinoma 115 37.4 39.1 23.5 head and neck carcinoma (nos) 114 25.4 53.5 21.1 kidney sarcomatoid carcinoma 111 29.7 42.3 27.9 unknown primary carcinoid 110 34.5 53.6 11.8 soft tissue sarcoma (nos) 109 37.6 44.0 18.3 stomach adenocarcinoma intestinal type 105 40.0 45.7 14.3 kidney wilms tumor 104 12.5 68.3 19.2 cervix neuroendocrine carcinoma 101 18.8 65.3 15.8 peritoneum adenocarcinoma 100 37.0 44.0 19.0 bladder small cell carcinoma 95 21.1 51.6 27.4 paraganglioma 95 11.6 73.7 14.7 lung adenoid cystic carcinoma 94 14.9 63.8 21.3 small intestine carcinoid 92 32.6 62.0 5.4 uterus leiomyosarcoma 91 31.9 50.5 17.6 esophagus neuroendocrine carcinoma 90 36.7 46.7 16.7 brain gliosarcoma 87 36.8 54.0 9.2 vulva melanoma 87 60.9 31.0 8.0 salivary gland mucoepidermoid carcinoma 85 24.7 49.4 25.9 rectum neuroendocrine carcinoma 84 10.7 66.7 22.6 soft tissue leiomyosarcoma 84 36.9 47.6 15.5

adrenal gland neuroblastoma 83 32.5 54.2 13.3 unknown primary carcinosarcoma 81 44.4 38.3 17.3 kidney chromophobe carcinoma 79 8.9 67.1 24.1 bladder neuroendocrine carcinoma 79 31.6 51.9 16.5 brain ganglioglioma 78 28.2 57.7 14.1 schwannoma 75 21.3 64.0 14.7 breast phyllodes tumor 71 21.1 73.2 5.6 urachus carcinoma 70 31.4 38.6 30.0 brain anaplastic meningioma 70 27.1 65.7 7.1 pancreas adenosquamous carcinoma 70 57.1 37.1 5.7 stomach neuroendocrine carcinoma 67 40.3 40.3 19.4 head and neck neuroendocrine carcinoma 66 25.8 57.6 16.7 cervix adenosquamous carcinoma 64 21.9 51.6 26.6 liver mixed hepatocellular 64 42.2 42.2 15.6 cholangiocarcinoma gallbladder carcinoma 63 42.9 34.9 22.2 cervix undifferentiated carcinoma 61 16.4 62.3 21.3 ovary germ cell tumor 61 23.0 59.0 18.0 lung typical carcinoid 60 26.7 58.3 15.0 nasopharynx and paranasal sinuses 59 25.4 54.2 20.3 adenocarcinoma breast neuroendocrine carcinoma 59 25.4 57.6 16.9 cervix clear cell adenocarcinoma 55 29.1 58.2 12.7 ovary sex cord stromal tumor (nos) 55 16.4 72.7 10.9 salivary gland carcinoma ex pleomorphic 55 34.5 54.5 10.9 adenoma vagina melanoma 54 59.3 33.3 7.4 vagina adenocarcinoma 53 35.8 50.9 13.2 soft tissue liposarcoma 53 26.4 64.2 9.4 cervix small cell carcinoma 52 26.9 53.8 19.2 head and neck mucoepidermoid carcinoma 52 30.8 53.8 15.4 colon gist 52 46.2 48.1 5.8 ovary small cell carcinoma 51 23.5 56.9 19.6 adrenal gland pheochromocytoma 51 19.6 70.6 9.8 urethra urothelial carcinoma 50 44.0 38.0 18.0 unknown primary undifferentiated large cell 49 30.6 46.9 22.4 carcinoma fallopian tube carcinosarcoma 47 70.2 19.1 10.6 liver hepatocellular carcinoma (flo) 44 29.5 56.8 13.6 uterus neuroendocrine carcinoma 44 22.7 63.6 13.6 testis germ cell tumor (mixed) 44 45.5 47.7 6.8 thyroid follicular oncocytic carcinoma 44 31.8 61.4 6.8 head and neck esthesioneuroblastoma 43 9.3 76.7 14.0 ovary neuroendocrine carcinoma 43 46.5 41.9 11.6 5

soft tissue angiosarcoma 41 22.0 48.8 29.3 testis germ cell tumor (seminoma) 41 58.5 29.3 12.2 salivary gland myoepithelial carcinoma 40 17.5 70.0 12.5 brain atypical teratoid rhabdoid tumor (atrt) 40 15.0 77.5 7.5 teratoma 39 20.5 66.7 12.8 spine ependymoma 38 13.2 36.8 50.0 mesothelioma (nos) 37 21.6 56.8 21.6 lung carcinosarcoma 37 35.1 51.4 13.5 unknown primary germ cell tumor 37 40.5 45.9 13.5 urethra adenocarcinoma 36 33.3 33.3 33.3 nasopharynx and paranasal sinuses 36 13.9 61.1 25.0 esthesioneuroblastoma brain craniopharyngioma 36 25.0 55.6 19.4 anus carcinoma (nos) 36 25.0 61.1 13.9 ovary serous tumor (lmp) 36 27.8 58.3 13.9 brain oligoastrocytoma 36 27.8 63.9 8.3 brain choroid plexus tumor 35 5.7 54.3 40.0 brain embryonal tumor 35 20.0 65.7 14.3 brain pleomorphic xanthoastrocytoma 35 28.6 57.1 14.3 skin extramammary pagets disease 35 54.3 34.3 11.4 soft tissue neurofibroma 34 26.5 50.0 23.5 brain astrocytoma pilomyxoid 34 11.8 82.4 5.9 pancreas solid pseudopapillary tumor 33 27.3 60.6 12.1 head and neck adenocarcinoma 32 37.5 53.1 9.4 parathyroid carcinoma 30 10.0 60.0 30.0 breast adenoid cystic carcinoma 29 6.9 69.0 24.1 breast ductal carcinoma in situ (dcis) 29 34.5 58.6 6.9 kidney collecting duct carcinoma 29 48.3 44.8 6.9 uterus sarcoma (nos) 29 55.2 41.4 3.4 pituitary adenoma 28 17.9 42.9 39.3 gallbladder adenosquamous carcinoma 28 42.9 42.9 14.3 urethra squamous cell carcinoma (scc) 27 33.3 48.1 18.5 brain pineoblastoma 27 14.8 77.8 7.4 mediastinum germ cell tumor 26 34.6 38.5 26.9 vulva adenocarcinoma 26 38.5 38.5 23.1 bone osteosarcoma 26 46.2 34.6 19.2 soft tissue nut midline carcinoma 26 15.4 65.4 19.2 colon carcinoid tumor 26 26.9 57.7 15.4 uterus endometrial stromal sarcoma 26 23.1 65.4 11.5 pancreas mucinous cystadenocarcinoma 23 39.1 52.2 8.7 gallbladder squamous cell carcinoma (scc) 22 50.0 36.4 13.6 kidney medullary carcinoma 22 22.7 68.2 9.1

soft tissue malignant peripheral nerve 22 45.5 45.5 9.1 sheath tumor (mpnst) soft tissue synovial sarcoma 21 28.6 52.4 19.0 thymus neuroendocrine carcinoma 21 9.5 71.4 19.0 esophagus adenosquamous carcinoma 21 52.4 38.1 9.5 brain hemangioblastoma 20 35.0 40.0 25.0 unknown primary endometrioid carcinoma 20 20.0 65.0 15.0 pineal parenchymal tumor 19 21.1 47.4 31.6 soft tissue myoepithelial carcinoma 19 5.3 73.7 21.1 soft tissue solitary fibrous tumor 19 26.3 57.9 15.8 brain neurocytoma 19 26.3 63.2 10.5 pancreas intraductal papillary mucinous 19 36.8 52.6 10.5 tumor (ipmt) peritoneum clear cell carcinoma 18 38.9 22.2 38.9 spine glioma (nos) 18 11.1 83.3 5.6 soft tissue ewing sarcoma 17 5.9 70.6 23.5 lung mucoepidermoid carcinoma 17 47.1 35.3 17.6 placenta trophoblastic tumor 17 17.6 64.7 17.6 anus basaloid carcinoma 17 17.6 70.6 11.8 soft tissue sarcoma undifferentiated 17 47.1 47.1 5.9 breast mucinous carcinoma 17 35.3 64.7 0.0 eye lacrimal duct carcinoma 17 41.2 58.8 0.0 skin desmoplastic melanoma 16 31.3 25.0 43.8 brain primitive neuroectoderm tumor (pnet) 16 12.5 68.8 18.8 head and neck ameloblastoma 16 0.0 81.3 18.8 uterus endometrial small cell carcinoma 16 25.0 62.5 12.5 pituitary carcinoma 15 6.7 73.3 20.0 rhabdomyosarcoma (nos) 15 60.0 20.0 20.0 bone giant cell tumor 15 26.7 60.0 13.3 soft tissue granular cell tumor 15 20.0 73.3 6.7 ovary sertoli-leydig cell tumor 14 21.4 57.1 21.4 rectum carcinoid tumor 14 21.4 64.3 14.3 brain germ cell tumor 13 38.5 46.2 15.4 breast lobular carcinoma in situ 13 30.8 69.2 0.0 soft tissue myxofibrosarcoma 12 41.7 16.7 41.7 trachea squamous cell carcinoma (scc) 12 25.0 41.7 33.3 head and neck spindle cell carcinoma 12 25.0 50.0 25.0 soft tissue angiomyolipoma 12 25.0 50.0 25.0 peritoneum mucinous carcinoma 11 36.4 27.3 36.4 trachea adenoid cystic carcinoma 11 18.2 45.5 36.4 vulva adenoid cystic carcinoma 11 9.1 63.6 27.3 duodenum neuroendocrine carcinoma 11 45.5 36.4 18.2 head and neck myoepithelial carcinoma 11 18.2 63.6 18.2

retroperitoneum germ cell tumor 11 36.4 45.5 18.2 soft tissue ganglioneuroma 11 36.4 45.5 18.2 soft tissue lymphangioma 11 0.0 81.8 18.2 vagina neuroendocrine carcinoma 11 9.1 72.7 18.2 breast angiosarcoma 11 0.0 90.9 9.1 lung pulmonary blastoma 11 36.4 54.5 9.1 placenta choriocarcinoma 11 45.5 45.5 9.1 soft tissue hemangioma 11 0.0 90.9 9.1 testis leydig cell tumor 11 72.7 27.3 0.0 uterus endometrial squamous cell 10 20.0 50.0 30.0 carcinoma (scc) skin atypical fibroxanthoma 10 40.0 40.0 20.0 peritoneum carcinosarcoma 10 50.0 40.0 10.0 unknown primary mucoepidermoid 10 40.0 50.0 10.0 carcinoma ureter small cell carcinoma 10 30.0 60.0 10.0 uterus adenosarcoma 10 50.0 40.0 10.0

Supplemental Table 2. CD274 positivity at different copy number cut-offs

Positivity Positivity Positivity Positivity Positivity w/ ploidy w/ w/ w/ Diagnosis n w/ ploidy + + 2 cut- ploidy + ploidy + ploidy + 1 cut-off off 3 cut-off 4 cut-off 8 cut-off lung adenocarcinoma 30396 14.99% 5.10% 1.80% 0.87% 0.16% colon adenocarcinoma (crc) 25618 24.83% 7.20% 2.00% 0.77% 0.06% breast carcinoma (nos) 14679 19.95% 8.50% 3.70% 2.06% 0.22% pancreas ductal adenocarcinoma 11698 8.45% 2.30% 0.50% 0.16% 0.01% prostate acinar adenocarcinoma 9466 16.17% 4.80% 1.00% 0.23% 0.01% lung squamous cell carcinoma (scc) 8852 17.77% 7.60% 3.70% 2.37% 0.44% breast invasive ductal carcinoma (idc) 8620 24.68% 11.60% 5.20% 2.61% 0.29% ovary serous carcinoma 7824 19.64% 7.10% 2.50% 1.16% 0.04% lung non-small cell lung carcinoma (nsclc) (nos) 6944 18.72% 7.50% 3.70% 1.97% 0.33% unknown primary adenocarcinoma 6329 13.75% 4.40% 1.50% 0.79% 0.14% rectum adenocarcinoma (crc) 5186 25.45% 8.40% 1.80% 0.69% 0.08% brain glioblastoma (gbm) 4787 9.19% 3.10% 0.90% 0.33% 0.00% liver cholangiocarcinoma 4653 12.14% 4.40% 1.30% 0.54% 0.11% bladder urothelial (transitional cell) carcinoma 4443 18.32% 6.50% 2.40% 1.22% 0.18% esophagus adenocarcinoma 4138 11.91% 2.90% 0.80% 0.39% 0.10% stomach adenocarcinoma (nos) 3979 14.35% 4.10% 1.30% 0.68% 0.18% head and neck squamous cell carcinoma (hnscc) 3511 25.69% 12.80% 6.50% 3.85% 1.17% skin melanoma 3501 8.03% 2.90% 0.90% 0.46% 0.20% unknown primary carcinoma (cup) (nos) 3432 18.65% 7.90% 3.40% 1.78% 0.32% uterus endometrial adenocarcinoma (nos) 3331 14.44% 5.00% 1.00% 0.51% 0.09% unknown primary melanoma 3038 10.90% 3.60% 1.30% 0.92% 0.26% ovary epithelial carcinoma 2564 20.20% 7.30% 2.80% 1.64% 0.08% lung small cell undifferentiated carcinoma 2493 26.84% 8.30% 2.90% 1.44% 0.24% pancreatobiliary carcinoma 2178 9.78% 3.30% 0.70% 0.28% 0.00% uterus endometrial adenocarcinoma 2113 11.64% 5.00% 1.20% 0.66% 0.00% endometrioid ovary high grade serous carcinoma 2025 20.84% 7.50% 3.30% 1.38% 0.05% uterus endometrial adenocarcinoma papillary 1971 21.21% 6.60% 1.90% 0.66% 0.05% serous kidney renal cell carcinoma 1675 11.70% 5.20% 1.60% 0.96% 0.42% gallbladder adenocarcinoma 1486 10.16% 2.80% 0.70% 0.20% 0.07% pancreas carcinoma (nos) 1481 10.47% 3.30% 1.10% 0.54% 0.00% gastroesophageal junction adenocarcinoma 1477 12.66% 2.60% 1.00% 0.34% 0.14% unknown primary squamous cell carcinoma (scc) 1414 23.34% 11.50% 6.20% 3.68% 0.78% fallopian tube serous carcinoma 1383 21.55% 8.70% 2.50% 1.45% 0.00% breast invasive lobular carcinoma (ilc) 1340 15.60% 4.80% 0.90% 0.37% 0.00% cervix squamous cell carcinoma (scc) 1317 31.06% 14.60% 6.20% 4.48% 1.37% kidney clear cell carcinoma 1299 10.47% 3.80% 0.70% 0.38% 0.08% uterus carcinosarcoma 1255 14.18% 5.00% 1.00% 0.40% 0.00%

liver hepatocellular carcinoma (hcc) 1230 11.71% 3.30% 1.10% 0.57% 0.16% unknown primary undifferentiated 1181 15.07% 4.50% 1.30% 0.51% 0.08% neuroendocrine carcinoma esophagus squamous cell carcinoma (scc) 1087 18.49% 8.70% 4.70% 2.48% 0.83% appendix adenocarcinoma 1009 24.18% 7.90% 2.70% 0.50% 0.00% thyroid papillary carcinoma 868 10.14% 3.30% 0.50% 0.12% 0.00% brain glioma (nos) 824 14.20% 5.30% 1.50% 0.85% 0.00% ovary clear cell carcinoma 811 12.21% 4.70% 1.10% 0.62% 0.00% lung large cell neuroendocrine carcinoma 770 18.96% 7.10% 3.40% 1.82% 0.78% anus squamous cell carcinoma (scc) 758 27.97% 10.40% 4.70% 3.30% 0.92% pleura mesothelioma 750 18.93% 6.80% 1.70% 0.67% 0.00% peritoneum serous carcinoma 738 19.24% 6.20% 1.80% 0.68% 0.00% skin squamous cell carcinoma (scc) 729 25.24% 12.30% 6.30% 3.84% 1.23% cervix adenocarcinoma 700 18.43% 6.40% 2.00% 1.00% 0.00% brain meningioma 700 8.86% 2.70% 0.10% 0.00% 0.00% pancreas islet cell tumor 691 27.64% 6.50% 1.30% 0.43% 0.14% brain anaplastic astrocytoma 653 11.33% 5.80% 0.80% 0.31% 0.00% bile duct adenocarcinoma 652 11.66% 2.90% 1.10% 0.46% 0.31% unknown primary urothelial carcinoma 647 16.23% 7.00% 2.90% 1.08% 0.31% small intestine adenocarcinoma 622 16.24% 5.30% 1.30% 0.48% 0.16% kidney urothelial carcinoma 620 16.45% 5.30% 2.10% 1.29% 0.48% unknown primary (nos) 570 20.18% 8.90% 3.20% 1.93% 0.18% brain astrocytoma 566 13.07% 5.10% 1.20% 0.18% 0.18% duodenum adenocarcinoma 562 15.66% 5.50% 1.40% 0.53% 0.18% ampullary adenocarcinoma 561 11.05% 2.90% 0.00% 0.00% 0.00% ovary endometrioid adenocarcinoma 540 17.59% 8.30% 2.20% 1.48% 0.19% unknown primary serous carcinoma 536 18.28% 5.40% 1.90% 0.37% 0.19% ovary carcinosarcoma 488 13.52% 4.10% 1.20% 0.61% 0.20% unknown primary gist 487 7.60% 2.70% 0.80% 0.41% 0.00% thyroid carcinoma (nos) 472 11.23% 3.80% 1.50% 0.64% 0.00% adrenal gland cortical carcinoma 424 24.06% 7.50% 0.50% 0.24% 0.00% vulva squamous cell carcinoma (scc) 423 33.57% 18.20% 9.70% 6.38% 0.47% unknown primary neuroendocrine tumor 422 13.51% 3.60% 0.70% 0.00% 0.00% thyroid anaplastic carcinoma 404 30.20% 14.10% 8.20% 3.96% 0.25% ovary granulosa cell tumor 371 12.67% 4.00% 0.80% 0.54% 0.00% ureter urothelial carcinoma 367 18.26% 5.20% 1.60% 0.82% 0.27% lung adenosquamous carcinoma 351 17.95% 7.40% 2.30% 1.14% 0.00% uterus endometrial adenocarcinoma clear cell 348 16.38% 6.30% 1.70% 0.57% 0.00% lung sarcomatoid carcinoma 347 32.85% 14.10% 6.30% 4.03% 0.58% stomach gist 346 7.51% 3.50% 1.20% 0.00% 0.00% salivary gland carcinoma (nos) 342 19.30% 8.80% 3.20% 1.75% 0.00% head and neck adenoid cystic carcinoma 340 20.88% 7.40% 2.10% 0.88% 0.00% prostate neuroendocrine carcinoma 340 20.29% 2.40% 0.90% 0.59% 0.00%

brain oligodendroglioma 329 4.56% 2.40% 0.00% 0.00% 0.00% salivary gland adenoid cystic carcinoma 317 19.24% 8.20% 2.20% 1.89% 0.32% brain astrocytoma pilocytic 312 16.99% 4.50% 1.60% 0.96% 0.00% unknown primary undifferentiated small cell 304 19.08% 4.90% 1.00% 0.66% 0.00% carcinoma breast metaplastic carcinoma 297 24.58% 12.50% 3.70% 2.36% 0.34% skin merkel cell carcinoma 296 10.14% 2.70% 0.70% 0.34% 0.00% colon neuroendocrine carcinoma 289 13.49% 4.50% 1.00% 0.69% 0.35% esophagus carcinoma (nos) 287 17.07% 4.50% 1.70% 0.70% 0.35% bladder carcinoma (nos) 282 20.21% 7.80% 2.80% 1.06% 0.71% eye intraocular melanoma 279 11.47% 4.70% 0.00% 0.00% 0.00% thymus carcinoma 272 23.16% 7.40% 1.80% 0.74% 0.37% thyroid medullary carcinoma 271 7.38% 2.20% 0.40% 0.00% 0.00% kidney renal papillary carcinoma 269 8.18% 2.60% 0.00% 0.00% 0.00% salivary gland adenocarcinoma 252 13.10% 3.60% 1.20% 0.79% 0.00% peritoneum mesothelioma 244 18.03% 8.20% 2.00% 0.41% 0.00% brain medulloblastoma 243 16.05% 6.20% 1.60% 0.41% 0.00% neuroblastoma 243 8.64% 0.80% 0.00% 0.00% 0.00% stomach adenocarcinoma diffuse type 225 16.89% 3.60% 0.90% 0.44% 0.00% small intestine gist 218 9.17% 3.20% 0.50% 0.46% 0.00% penis squamous cell carcinoma (scc) 207 35.27% 17.90% 9.20% 7.25% 2.42% prostate undifferentiated carcinoma 194 22.16% 7.70% 1.50% 0.52% 0.00% brain ependymoma 193 28.50% 4.10% 0.50% 0.52% 0.00% soft tissue fibromatosis 191 8.90% 0.50% 0.00% 0.00% 0.00% skin basal cell carcinoma 190 25.26% 11.60% 6.30% 2.11% 1.05% uterus endometrial adenocarcinoma mixed 187 17.11% 7.00% 3.20% 1.07% 0.00% histology ovary carcinoma mixed histology 174 15.52% 5.70% 1.10% 0.57% 0.00% bladder adenocarcinoma 171 30.41% 8.20% 2.90% 1.75% 0.58% appendix goblet cell carcinoid (gcc) 171 23.39% 8.20% 1.80% 1.17% 0.00% lung large cell carcinoma 168 13.69% 6.00% 3.00% 0.60% 0.00% skin adnexal carcinoma 167 22.16% 6.60% 3.00% 1.80% 0.00% thyroid follicular carcinoma 165 14.55% 7.90% 1.20% 0.61% 0.00% ovary mucinous carcinoma 164 12.20% 6.70% 3.70% 1.22% 0.00% thymus thymoma (nos) 159 33.96% 7.50% 1.30% 0.63% 0.00% nasopharynx and paranasal sinuses 157 20.38% 9.60% 4.50% 3.82% 0.64% undifferentiated carcinoma bladder squamous cell carcinoma (scc) 156 24.36% 7.10% 3.20% 1.28% 0.00% salivary gland duct carcinoma 154 12.99% 5.80% 1.90% 1.95% 0.00% lung atypical carcinoid 151 9.93% 1.30% 0.70% 0.66% 0.00% unknown primary adenoid cystic carcinoma 144 18.06% 4.90% 0.70% 0.69% 0.00% unknown primary sarcomatoid carcinoma 141 34.75% 18.40% 7.10% 3.55% 0.71% vagina squamous cell carcinoma (scc) 141 28.37% 9.20% 4.30% 1.42% 0.00% head and neck melanoma 140 12.14% 4.30% 3.60% 2.14% 0.00% small intestine neuroendocrine carcinoma 140 7.14% 2.10% 0.70% 0.71% 0.00%

bone chordoma 139 12.23% 4.30% 0.00% 0.00% 0.00% kidney carcinoma (nos) 136 12.50% 5.90% 0.70% 0.00% 0.00% testis germ cell tumor (non-seminoma) 133 15.79% 3.00% 2.30% 1.50% 0.00% ovary low grade serous carcinoma 131 6.11% 1.50% 0.00% 0.00% 0.00% prostate ductal adenocarcinoma 130 12.31% 2.30% 0.80% 0.00% 0.00% anus melanoma 129 6.20% 2.30% 1.60% 1.55% 0.00% appendix mucinous neoplasm 128 25.78% 6.30% 0.00% 0.00% 0.00% pancreas acinar cell carcinoma 128 12.50% 4.70% 1.60% 1.56% 1.56% salivary gland acinic cell tumor 125 18.40% 4.80% 2.40% 1.60% 0.00% rectum squamous cell carcinoma (scc) 119 31.09% 15.10% 5.00% 4.20% 2.52% brain anaplastic oligodendroglioma 117 6.84% 4.30% 0.90% 0.00% 0.00% nasopharynx and paranasal sinuses squamous cell 115 24.35% 13.00% 5.20% 4.35% 1.74% carcinoma (scc) fallopian tube adenocarcinoma 115 23.48% 7.00% 2.60% 1.74% 0.00% head and neck carcinoma (nos) 114 21.05% 12.30% 5.30% 2.63% 0.00% kidney sarcomatoid carcinoma 111 27.03% 13.50% 9.00% 6.31% 3.60% unknown primary carcinoid 110 11.82% 3.60% 1.80% 0.91% 0.00% soft tissue sarcoma (nos) 109 17.43% 3.70% 0.90% 0.00% 0.00% stomach adenocarcinoma intestinal type 105 14.29% 6.70% 1.00% 0.95% 0.95% kidney wilms tumor 104 19.23% 3.80% 1.00% 0.00% 0.00% cervix neuroendocrine carcinoma 101 15.84% 6.90% 3.00% 0.99% 0.00% peritoneum adenocarcinoma 100 19.00% 6.00% 2.00% 0.00% 0.00% bladder small cell carcinoma 95 25.26% 6.30% 2.10% 1.05% 0.00% paraganglioma 95 13.68% 4.20% 2.10% 1.05% 0.00% lung adenoid cystic carcinoma 94 21.28% 10.60% 2.10% 0.00% 0.00% small intestine carcinoid 92 5.43% 2.20% 0.00% 0.00% 0.00% uterus leiomyosarcoma 91 17.58% 3.30% 0.00% 0.00% 0.00% esophagus neuroendocrine carcinoma 90 16.67% 6.70% 3.30% 1.11% 1.11% brain gliosarcoma 87 9.20% 2.30% 0.00% 0.00% 0.00% vulva melanoma 87 8.05% 4.60% 2.30% 2.30% 0.00% salivary gland mucoepidermoid carcinoma 85 25.88% 7.10% 0.00% 0.00% 0.00% rectum neuroendocrine carcinoma 84 22.62% 8.30% 3.60% 2.38% 0.00% soft tissue leiomyosarcoma 84 15.48% 6.00% 3.60% 0.00% 0.00% adrenal gland neuroblastoma 83 13.25% 8.40% 1.20% 0.00% 0.00% unknown primary carcinosarcoma 81 17.28% 7.40% 4.90% 2.47% 0.00% kidney chromophobe carcinoma 79 24.05% 7.60% 2.50% 0.00% 0.00% bladder neuroendocrine carcinoma 79 16.46% 1.30% 0.00% 0.00% 0.00% brain ganglioglioma 78 14.10% 2.60% 1.30% 1.28% 0.00% schwannoma 75 14.67% 4.00% 0.00% 0.00% 0.00% breast phyllodes tumor 71 5.63% 0.00% 0.00% 0.00% 0.00% urachus carcinoma 70 28.57% 7.10% 1.40% 0.00% 0.00% brain anaplastic meningioma 70 7.14% 1.40% 0.00% 0.00% 0.00% pancreas adenosquamous carcinoma 70 5.71% 1.40% 0.00% 0.00% 0.00%

stomach neuroendocrine carcinoma 67 17.91% 9.00% 1.50% 0.00% 0.00% head and neck neuroendocrine carcinoma 66 16.67% 3.00% 1.50% 1.52% 0.00% cervix adenosquamous carcinoma 64 26.56% 7.80% 4.70% 3.13% 0.00% liver mixed hepatocellular cholangiocarcinoma 64 15.63% 6.30% 1.60% 1.56% 0.00% gallbladder carcinoma 63 22.22% 3.20% 1.60% 1.59% 0.00% cervix undifferentiated carcinoma 61 21.31% 9.80% 6.60% 1.64% 0.00% ovary germ cell tumor 61 18.03% 3.30% 0.00% 0.00% 0.00% lung typical carcinoid 60 15.00% 3.30% 1.70% 1.67% 0.00% nasopharynx and paranasal sinuses 59 20.34% 5.10% 3.40% 1.69% 0.00% adenocarcinoma breast neuroendocrine carcinoma 59 16.95% 5.10% 1.70% 0.00% 0.00% cervix clear cell adenocarcinoma 55 12.73% 7.30% 0.00% 0.00% 0.00% ovary sex cord stromal tumor (nos) 55 10.91% 3.60% 1.80% 0.00% 0.00% salivary gland carcinoma ex pleomorphic adenoma 55 10.91% 3.60% 1.80% 0.00% 0.00% vagina melanoma 54 7.41% 5.60% 1.90% 1.85% 0.00% vagina adenocarcinoma 53 13.21% 1.90% 1.90% 1.89% 1.89% soft tissue liposarcoma 53 9.43% 7.50% 5.70% 5.66% 0.00% cervix small cell carcinoma 52 19.23% 3.80% 1.90% 0.00% 0.00% head and neck mucoepidermoid carcinoma 52 15.38% 1.90% 1.90% 1.92% 0.00% colon gist 52 5.77% 3.80% 0.00% 0.00% 0.00% ovary small cell carcinoma 51 19.61% 5.90% 2.00% 1.96% 0.00% adrenal gland pheochromocytoma 51 9.80% 3.90% 2.00% 0.00% 0.00% urethra urothelial carcinoma 50 18.00% 4.00% 0.00% 0.00% 0.00% unknown primary undifferentiated large cell 49 22.45% 6.10% 2.00% 0.00% 0.00% carcinoma fallopian tube carcinosarcoma 47 10.64% 4.30% 2.10% 0.00% 0.00% liver hepatocellular carcinoma (flo) 44 13.64% 4.50% 2.30% 0.00% 0.00% uterus neuroendocrine carcinoma 44 13.64% 0.00% 0.00% 0.00% 0.00% testis germ cell tumor (mixed) 44 6.82% 2.30% 0.00% 0.00% 0.00% thyroid follicular oncocytic carcinoma 44 6.82% 2.30% 0.00% 0.00% 0.00% head and neck esthesioneuroblastoma 43 13.95% 0.00% 0.00% 0.00% 0.00% ovary neuroendocrine carcinoma 43 11.63% 7.00% 0.00% 0.00% 0.00% soft tissue angiosarcoma 41 29.27% 12.20% 2.40% 0.00% 0.00% testis germ cell tumor (seminoma) 41 12.20% 2.40% 0.00% 0.00% 0.00% salivary gland myoepithelial carcinoma 40 12.50% 2.50% 2.50% 2.50% 0.00% brain atypical teratoid rhabdoid tumor (atrt) 40 7.50% 5.00% 0.00% 0.00% 0.00% teratoma 39 12.82% 0.00% 0.00% 0.00% 0.00% spine ependymoma 38 50.00% 13.20% 10.50% 7.89% 0.00% mesothelioma (nos) 37 21.62% 2.70% 0.00% 0.00% 0.00% lung carcinosarcoma 37 13.51% 8.10% 2.70% 0.00% 0.00% unknown primary germ cell tumor 37 13.51% 2.70% 0.00% 0.00% 0.00% urethra adenocarcinoma 36 33.33% 0.00% 0.00% 0.00% 0.00% nasopharynx and paranasal sinuses 36 25.00% 13.90% 2.80% 0.00% 0.00% esthesioneuroblastoma brain craniopharyngioma 36 19.44% 5.60% 0.00% 0.00% 0.00%

anus carcinoma (nos) 36 13.89% 5.60% 2.80% 0.00% 0.00% ovary serous tumor (lmp) 36 13.89% 8.30% 0.00% 0.00% 0.00% brain oligoastrocytoma 36 8.33% 5.60% 0.00% 0.00% 0.00% brain choroid plexus tumor 35 37.14% 11.40% 0.00% 0.00% 0.00% brain embryonal tumor 35 14.29% 2.90% 0.00% 0.00% 0.00% brain pleomorphic xanthoastrocytoma 35 14.29% 8.60% 0.00% 0.00% 0.00% skin extramammary pagets disease 35 11.43% 2.90% 0.00% 0.00% 0.00% soft tissue neurofibroma 34 23.53% 8.80% 0.00% 0.00% 0.00% brain astrocytoma pilomyxoid 34 2.94% 0.00% 0.00% 0.00% 0.00% pancreas solid pseudopapillary tumor 33 12.12% 6.10% 3.00% 0.00% 0.00% head and neck adenocarcinoma 32 9.38% 3.10% 0.00% 0.00% 0.00% parathyroid carcinoma 30 30.00% 10.00% 0.00% 0.00% 0.00% breast adenoid cystic carcinoma 29 24.14% 3.40% 3.40% 0.00% 0.00% breast ductal carcinoma in situ (dcis) 29 6.90% 3.40% 0.00% 0.00% 0.00% kidney collecting duct carcinoma 29 6.90% 6.90% 0.00% 0.00% 0.00% uterus sarcoma (nos) 29 3.45% 3.40% 3.40% 3.45% 0.00% pituitary adenoma 28 39.29% 17.90% 3.60% 3.57% 0.00% gallbladder adenosquamous carcinoma 28 14.29% 3.60% 0.00% 0.00% 0.00% urethra squamous cell carcinoma (scc) 27 18.52% 3.70% 0.00% 0.00% 0.00% brain pineoblastoma 27 7.41% 3.70% 0.00% 0.00% 0.00% mediastinum germ cell tumor 26 26.92% 3.80% 0.00% 0.00% 0.00% vulva adenocarcinoma 26 23.08% 7.70% 3.80% 0.00% 0.00% bone osteosarcoma 26 19.23% 3.80% 0.00% 0.00% 0.00% soft tissue nut midline carcinoma 26 19.23% 0.00% 0.00% 0.00% 0.00% colon carcinoid tumor 26 15.38% 3.80% 0.00% 0.00% 0.00% uterus endometrial stromal sarcoma 26 11.54% 3.80% 3.80% 0.00% 0.00% pancreas mucinous cystadenocarcinoma 23 8.70% 0.00% 0.00% 0.00% 0.00% gallbladder squamous cell carcinoma (scc) 22 13.64% 0.00% 0.00% 0.00% 0.00% kidney medullary carcinoma 22 9.09% 4.50% 0.00% 0.00% 0.00% soft tissue malignant peripheral nerve sheath 22 9.09% 0.00% 0.00% 0.00% 0.00% tumor (mpnst) soft tissue synovial sarcoma 21 19.05% 0.00% 0.00% 0.00% 0.00% thymus neuroendocrine carcinoma 21 19.05% 4.80% 4.80% 0.00% 0.00% esophagus adenosquamous carcinoma 21 9.52% 4.80% 4.80% 0.00% 0.00% brain hemangioblastoma 20 25.00% 5.00% 0.00% 0.00% 0.00% unknown primary endometrioid carcinoma 20 15.00% 5.00% 5.00% 0.00% 0.00% pineal parenchymal tumor 19 31.58% 10.50% 5.30% 5.26% 0.00% soft tissue myoepithelial carcinoma 19 21.05% 5.30% 0.00% 0.00% 0.00% soft tissue solitary fibrous tumor 19 15.79% 0.00% 0.00% 0.00% 0.00% brain neurocytoma 19 10.53% 0.00% 0.00% 0.00% 0.00% pancreas intraductal papillary mucinous tumor 19 10.53% 5.30% 0.00% 0.00% 0.00% (ipmt) peritoneum clear cell carcinoma 18 38.89% 27.80% 11.10% 11.11% 0.00% spine glioma (nos) 18 5.56% 5.60% 0.00% 0.00% 0.00%

soft tissue ewing sarcoma 17 23.53% 17.60% 0.00% 0.00% 0.00% lung mucoepidermoid carcinoma 17 17.65% 11.80% 0.00% 0.00% 0.00% placenta trophoblastic tumor 17 17.65% 0.00% 0.00% 0.00% 0.00% anus basaloid carcinoma 17 11.76% 0.00% 0.00% 0.00% 0.00% soft tissue sarcoma undifferentiated 17 5.88% 0.00% 0.00% 0.00% 0.00% breast mucinous carcinoma 17 0.00% 0.00% 0.00% 0.00% 0.00% eye lacrimal duct carcinoma 17 0.00% 0.00% 0.00% 0.00% 0.00% skin desmoplastic melanoma 16 43.75% 18.80% 0.00% 0.00% 0.00% brain primitive neuroectoderm tumor (pnet) 16 18.75% 12.50% 6.30% 6.25% 0.00% head and neck ameloblastoma 16 18.75% 6.30% 0.00% 0.00% 0.00% uterus endometrial small cell carcinoma 16 12.50% 0.00% 0.00% 0.00% 0.00% pituitary carcinoma 15 20.00% 6.70% 6.70% 0.00% 0.00% rhabdomyosarcoma (nos) 15 13.33% 13.30% 0.00% 0.00% 0.00% bone giant cell tumor 15 13.33% 13.30% 0.00% 0.00% 0.00% soft tissue granular cell tumor 15 6.67% 0.00% 0.00% 0.00% 0.00% ovary sertoli-leydig cell tumor 14 21.43% 0.00% 0.00% 0.00% 0.00% rectum carcinoid tumor 14 14.29% 0.00% 0.00% 0.00% 0.00% brain germ cell tumor 13 15.38% 0.00% 0.00% 0.00% 0.00% breast lobular carcinoma in situ 13 0.00% 0.00% 0.00% 0.00% 0.00% soft tissue myxofibrosarcoma 12 41.67% 25.00% 8.30% 8.33% 8.33% trachea squamous cell carcinoma (scc) 12 33.33% 16.70% 8.30% 8.33% 0.00% head and neck spindle cell carcinoma 12 25.00% 8.30% 0.00% 0.00% 0.00% soft tissue angiomyolipoma 12 25.00% 16.70% 8.30% 8.33% 0.00% peritoneum mucinous carcinoma 11 36.36% 27.30% 0.00% 0.00% 0.00% trachea adenoid cystic carcinoma 11 36.36% 9.10% 9.10% 0.00% 0.00% vulva adenoid cystic carcinoma 11 27.27% 18.20% 0.00% 0.00% 0.00% duodenum neuroendocrine carcinoma 11 18.18% 9.10% 0.00% 0.00% 0.00% head and neck myoepithelial carcinoma 11 18.18% 0.00% 0.00% 0.00% 0.00% retroperitoneum germ cell tumor 11 18.18% 9.10% 0.00% 0.00% 0.00% soft tissue ganglioneuroma 11 18.18% 9.10% 0.00% 0.00% 0.00% soft tissue lymphangioma 11 18.18% 9.10% 0.00% 0.00% 0.00% vagina neuroendocrine carcinoma 11 18.18% 0.00% 0.00% 0.00% 0.00% breast angiosarcoma 11 9.09% 0.00% 0.00% 0.00% 0.00% lung pulmonary blastoma 11 9.09% 0.00% 0.00% 0.00% 0.00% placenta choriocarcinoma 11 9.09% 0.00% 0.00% 0.00% 0.00% soft tissue hemangioma 11 9.09% 0.00% 0.00% 0.00% 0.00% testis leydig cell tumor 11 0.00% 0.00% 0.00% 0.00% 0.00% uterus endometrial squamous cell carcinoma (scc) 10 30.00% 20.00% 0.00% 0.00% 0.00% skin atypical fibroxanthoma 10 20.00% 10.00% 10.00% 0.00% 0.00% peritoneum carcinosarcoma 10 10.00% 0.00% 0.00% 0.00% 0.00% unknown primary mucoepidermoid carcinoma 10 10.00% 0.00% 0.00% 0.00% 0.00% ureter small cell carcinoma 10 10.00% 0.00% 0.00% 0.00% 0.00% uterus adenosarcoma 10 0.00% 0.00% 0.00% 0.00% 0.00%

Supplemental Table 3. Sensitivity, specificity, positive predictive value, and negative predictive value of CD274 positivity (based on different cut-offs) when compared to PD-L1 immunohistochemistry positivity Positive Negative Diagnosis Cut-off Sensitivity Specificity predictive predictive value value Breast carcinoma (n = 3833) ploidy + 1 30% 83% 55% 63% ploidy + 2 15% 94% 63% 61% ploidy + 3 7% 98% 72% 60% ploidy + 4 4% 99% 74% 59% ploidy + 5 3% 99% 72% 59% ploidy + 6 2% 100% 77% 59% ploidy + 7 1% 100% 90% 59% ploidy + 8 1% 100% 92% 59% ploidy + 9 1% 100% 100% 59% ploidy + 10 1% 100% 100% 59% Cervical carcinoma (n = 701) ploidy + 1 32% 88% 94% 19% ploidy + 2 15% 94% 94% 17% ploidy + 3 6% 97% 92% 16% ploidy + 4 3% 100% 100% 16% ploidy + 5 2% 100% 100% 15% ploidy + 6 2% 100% 100% 15% ploidy + 7 1% 100% 100% 15% ploidy + 8 1% 100% 100% 15% ploidy + 9 1% 100% 100% 15% ploidy + 10 1% 100% 100% 15% Esophageal SCC (n= 208) ploidy + 1 27% 88% 77% 43% ploidy + 2 17% 96% 88% 42% ploidy + 3 10% 100% 100% 42% ploidy + 4 3% 100% 100% 40% ploidy + 5 2% 100% 100% 40% ploidy + 6 2% 100% 100% 40% ploidy + 7 2% 100% 100% 40% ploidy + 8 2% 100% 100% 39% ploidy + 9 1% 100% 100% 39% ploidy + 10 1% 100% 100% 39% Gastric/esophageal adenocarcinoma (n=1993) ploidy + 1 14% 89% 86% 18% ploidy + 2 4% 97% 87% 18%

ploidy + 3 1% 100% 95% 17% ploidy + 4 1% 100% 100% 17% ploidy + 5 0% 100% 100% 17% ploidy + 6 0% 100% 100% 17% ploidy + 7 0% 100% 100% 17% ploidy + 8 0% 100% 100% 17% ploidy + 9 0% 100% 100% 17% ploidy + 10 0% 100% 100% 17% HNSCC (n = 655) ploidy + 1 27% 96% 99% 5% ploidy + 2 14% 96% 99% 4% ploidy + 3 8% 100% 100% 4% ploidy + 4 4% 100% 100% 4% ploidy + 5 3% 100% 100% 4% ploidy + 6 3% 100% 100% 4% ploidy + 7 2% 100% 100% 4% ploidy + 8 2% 100% 100% 4% ploidy + 9 1% 100% 100% 4% ploidy + 10 1% 100% 100% 4% NSCLC (n = 20755) ploidy + 1 22% 91% 77% 45% ploidy + 2 9% 98% 84% 43% ploidy + 3 4% 99% 91% 42% ploidy + 4 2% 100% 95% 42% ploidy + 5 2% 100% 95% 42% ploidy + 6 1% 100% 96% 41% ploidy + 7 1% 100% 95% 41% ploidy + 8 1% 100% 95% 41% ploidy + 9 1% 100% 95% 41% ploidy + 10 0% 100% 94% 41% Urothelial carcinoma (n = 1742) ploidy + 1 25% 87% 64% 55% ploidy + 2 12% 97% 77% 54% ploidy + 3 5% 99% 80% 52% ploidy + 4 3% 100% 87% 52% ploidy + 5 2% 100% 88% 52% ploidy + 6 1% 100% 91% 51% ploidy + 7 1% 100% 100% 51% ploidy + 8 1% 100% 100% 51% ploidy + 9 0% 100% 100% 51% ploidy + 10 0% 100% 100% 51%

Huang RS.P, et al. J Immunother Cancer 2021; 9:e002680. doi: 10.1136/jitc-2021-002680